[Biologics in inflammatory bowel diseases]
Philip Esters1, Christopher Hackenberg1, Herrmann Schulze1
1Medizinische Klinik I, Agaplesion Markus Krankenhaus, Wilhelm-Epstein-Str. 4, 60431, Frankfurt am Main, Deutschland.
Der Internist
|January 17, 2022
Summary
Biologics offer advanced treatment options for inflammatory bowel disease (IBD), improving patient care and quality of life. While effective, the increasing number of biologic therapies complicates treatment algorithms for IBD.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Chronic inflammatory bowel disease (IBD) management has evolved significantly over 20 years.
- Approved biologics offer diverse treatment alternatives, enhancing patient care and quality of life.
- Biologics contribute to reduced long-term disability and morbidity in IBD patients.
Purpose of the Study:
- To provide an overview of current biologic implementation in IBD treatment.
- To present current clinical management strategies for IBD using biologics.
- To offer an outlook on future biologic treatment options for IBD.
Main Methods:
- Literature search conducted in PubMed and ClinicalTrials.gov.
- Evaluation of current German and European IBD treatment guidelines.
- Review of expert recommendations for biologic therapy in IBD.
Main Results:
- A continuous increase in IBD treatment options, particularly biologics, since the late 1990s.
- Demonstrated safety and efficacy of biologics in large randomized clinical studies.
- Biologics are standard for moderate-to-severe IBD, steroid-refractory, or steroid-dependent cases.
Conclusions:
- Diverse IBD treatment options, including biologics, improve patient care.
- Increasing biologic options enhance individualized IBD treatment strategies.
- This article synthesizes current and future biologic treatments for IBD within treatment algorithms.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
224
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
224
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
250
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
250
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
235
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
235
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
444
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
444
01:29Drugs for Treatment of Ulcerative Colitis in IBD
261
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
261